TY - JOUR
T1 - Let‐7a‐5p, mir‐100‐5p, mir‐101‐3p, and mir‐199a‐3p hyperexpression as potential predictive biomarkers in early breast cancer patients
AU - Fuso, P.
AU - Di, Salvatore M.
AU - Santonocito, Concetta
AU - Guarino, D.
AU - Autilio, C.
AU - Mule, A.
AU - Arciuolo, Damiano
AU - Rinninella, A.
AU - Mignone, F.
AU - Ramundo, M.
AU - Di, Stefano B.
AU - Orlandi, A.
AU - Capoluongo, E.
AU - Nicolotti, N.
AU - Franceschini, Gianluca
AU - Sanchez, A. M.
AU - Tortora, Giampaolo
AU - Scambia, G.
AU - Barone, C.
AU - Cassano, Alessandra
PY - 2021
Y1 - 2021
N2 - Background: The aim of this study is to identify miRNAs able to predict the outcomes in breast cancer patients after neoadjuvant chemotherapy (NAC). Patients and methods: We retrospec-tively analyzed 24 patients receiving NAC and not reaching pathologic complete response (pCR). miRNAs were analyzed using an Illumina Next‐Generation‐Sequencing (NGS) system. Results: Event‐free survival (EFS) and overall survival (OS) were significantly higher in patients with up-regulation of let‐7a‐5p (EFS p = 0.006; OS p = 0.0001), mirR‐100‐5p (EFS s p = 0.01; OS p = 0.03), miR‐ 101‐3p (EFS p = 0.05; OS p = 0.01), and miR‐199a‐3p (EFS p = 0.02; OS p = 0.01) in post‐NAC samples, independently from breast cancer subtypes. At multivariate analysis, only let‐7a‐5p was significantly associated with EFS (p = 0.009) and OS (p = 0.0008). Conclusion: Up‐regulation of the above miRNAs could represent biomarkers in breast cancer.
AB - Background: The aim of this study is to identify miRNAs able to predict the outcomes in breast cancer patients after neoadjuvant chemotherapy (NAC). Patients and methods: We retrospec-tively analyzed 24 patients receiving NAC and not reaching pathologic complete response (pCR). miRNAs were analyzed using an Illumina Next‐Generation‐Sequencing (NGS) system. Results: Event‐free survival (EFS) and overall survival (OS) were significantly higher in patients with up-regulation of let‐7a‐5p (EFS p = 0.006; OS p = 0.0001), mirR‐100‐5p (EFS s p = 0.01; OS p = 0.03), miR‐ 101‐3p (EFS p = 0.05; OS p = 0.01), and miR‐199a‐3p (EFS p = 0.02; OS p = 0.01) in post‐NAC samples, independently from breast cancer subtypes. At multivariate analysis, only let‐7a‐5p was significantly associated with EFS (p = 0.009) and OS (p = 0.0008). Conclusion: Up‐regulation of the above miRNAs could represent biomarkers in breast cancer.
KW - Breast cancer treatment
KW - Chemotherapy
KW - Integrated ther-apies
KW - MiRNAs
KW - Next‐generation‐sequencing
KW - Personalized medicine
KW - Precision medicine
KW - Subtypes breast cancer
KW - Target therapy
KW - Breast cancer treatment
KW - Chemotherapy
KW - Integrated ther-apies
KW - MiRNAs
KW - Next‐generation‐sequencing
KW - Personalized medicine
KW - Precision medicine
KW - Subtypes breast cancer
KW - Target therapy
UR - https://publicatt.unicatt.it/handle/10807/190389
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85113804265&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85113804265&origin=inward
U2 - 10.3390/jpm11080816
DO - 10.3390/jpm11080816
M3 - Article
SN - 2075-4426
VL - 11
SP - 1
EP - 17
JO - Journal of Personalized Medicine
JF - Journal of Personalized Medicine
IS - 8
ER -
